Heterologous Prime Boost Vaccination Induces Protective Melanoma-Specific CD8
Cancer vaccination
Melanoma
Viral Vectors
gp100
heterologous prime boost
Journal
Molecular therapy oncolytics
ISSN: 2372-7705
Titre abrégé: Mol Ther Oncolytics
Pays: United States
ID NLM: 101666776
Informations de publication
Date de publication:
16 Dec 2020
16 Dec 2020
Historique:
received:
12
06
2020
accepted:
06
10
2020
entrez:
19
11
2020
pubmed:
20
11
2020
medline:
20
11
2020
Statut:
epublish
Résumé
Cancer vaccination aims at inducing an adaptive immune response against tumor-derived antigens. In this study, we utilize recombinant human adenovirus serotype 5 (rAd5) and recombinant lymphocytic choriomeningitis virus (rLCMV)-based vectors expressing the melanocyte differentiation antigen gp100. In contrast to single or homologous vaccination, a heterologous prime boost vaccination starting with a rAd5-gp100 prime immunization followed by a rLCMV-gp100 boost injection induces a high magnitude of polyfunctional gp100-specific CD8
Identifiants
pubmed: 33209978
doi: 10.1016/j.omto.2020.10.001
pii: S2372-7705(20)30152-2
pmc: PMC7658660
doi:
Types de publication
Journal Article
Langues
eng
Pagination
179-187Informations de copyright
© 2020 The Author(s).
Références
Nat Med. 2010 Mar;16(3):339-45
pubmed: 20139992
J Immunother. 2012 Jun;35(5):374-84
pubmed: 22576342
Nature. 2017 Aug 31;548(7669):537-542
pubmed: 28783722
Cancer Immunol Immunother. 2013 May;62(5):897-908
pubmed: 23589107
Nat Med. 2011 Aug 21;17(9):1128-31
pubmed: 21857654
Lancet Oncol. 2005 May;6(5):271-8
pubmed: 15863374
Blood. 2000 Jan 1;95(1):212-20
pubmed: 10607705
J Virol. 1996 Nov;70(11):7498-509
pubmed: 8892868
J Exp Med. 1982 Apr 1;155(4):1063-74
pubmed: 6460831
J Immunol. 2011 Aug 15;187(4):1788-96
pubmed: 21746967
JAMA. 2000 Dec 20;284(23):3040-2
pubmed: 11122592
Cancer Immunol Immunother. 2013 Jan;62(1):171-82
pubmed: 23011589
Nat Med. 2004 Sep;10(9):909-15
pubmed: 15340416
Cancer Immunol Immunother. 2012 Oct;61(10):1791-804
pubmed: 22426890
Cancer Immunol Res. 2015 Aug;3(8):915-25
pubmed: 25977260
Cancer Control. 2013 Oct;20(4):289-97
pubmed: 24077405
Vaccines (Basel). 2016 Nov 17;4(4):
pubmed: 27869670
Adv Cancer Res. 2014;121:67-124
pubmed: 24889529
Clin Cancer Res. 2006 Apr 15;12(8):2526-37
pubmed: 16638862
Cancer Immunol Immunother. 2015 Apr;64(4):507-18
pubmed: 25662405
Nat Med. 2001 Jan;7(1):33-40
pubmed: 11135613
N Engl J Med. 2011 Jun 2;364(22):2119-27
pubmed: 21631324
J Virol. 2012 Aug;86(15):7760-70
pubmed: 22593152
Nature. 2012 Oct 18;490(7420):412-6
pubmed: 23051752
J Gene Med. 2004 Feb;6 Suppl 1:S164-71
pubmed: 14978759
J Infect Dis. 2020 Apr 21;:
pubmed: 32313928
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Mol Ther. 2017 Nov 1;25(11):2533-2545
pubmed: 28803862
Cell Immunol. 2016 Dec;310:89-98
pubmed: 27545090
J Immunother. 2018 Apr;41(3):125-129
pubmed: 29293165
Genes Dis. 2017 Jun;4(2):43-63
pubmed: 28944281
Curr Opin Immunol. 2016 Aug;41:47-54
pubmed: 27286566
Hum Vaccin Immunother. 2016 Aug 2;12(8):2064-2074
pubmed: 27105067
Cancer Immunol Immunother. 2013 Aug;62(8):1293-301
pubmed: 23624851
JCI Insight. 2019 May 16;4(10):
pubmed: 31092734
Blood. 2010 Mar 25;115(12):2397-406
pubmed: 20118405
Oncoimmunology. 2016 Jul 8;5(9):e1207842
pubmed: 27757300
Front Oncol. 2019 Apr 16;9:279
pubmed: 31058083
Clin Cancer Res. 2008 Sep 1;14(17):5610-8
pubmed: 18765555
Cancer. 2006 Feb 15;106(4):890-9
pubmed: 16404742
Int J Cancer. 1999 Nov 12;83(4):532-40
pubmed: 10508491
Proc Natl Acad Sci U S A. 2011 Apr 5;108(14):5724-9
pubmed: 21422297
Lancet. 2008 Nov 29;372(9653):1881-1893
pubmed: 19012954
J Immunother. 2007 Jan;30(1):40-53
pubmed: 17198082
Int J Cancer. 2012 Sep 1;131(5):E670-80
pubmed: 22139992
Hum Gene Ther. 2000 Oct 10;11(15):2105-16
pubmed: 11044912
Clin Cancer Res. 2011 Jul 1;17(13):4550-7
pubmed: 21498393
J Exp Med. 2003 Aug 18;198(4):569-80
pubmed: 12925674
J Exp Med. 1998 Jul 20;188(2):277-86
pubmed: 9670040
Curr Opin Biotechnol. 2007 Dec;18(6):546-56
pubmed: 18063357
Methods Mol Biol. 2016;1404:351-364
pubmed: 27076310
Cancer Res. 2007 Apr 1;67(7):3387-95
pubmed: 17409449
J Immunol. 1995 Apr 15;154(8):3961-8
pubmed: 7706734
Clin Cancer Res. 2017 Nov 15;23(22):6771-6780
pubmed: 28855352